Exemestane: A review of its use as adjuvant treatment for early breast cancer in postmenopausal women

American Journal of Cancer

Volumn 5, Issue 4, 2006, Pages 259-272

  Moen, Marit D ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

Early breast cancer; Exemestane; Pharmacodynamics; Pharmacokinetics; Postmenopausal; Therapeutic use; Tolerability

Indexed keywords

ALDOSTERONE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450 3A4; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FOLLITROPIN; HYDROCORTISONE; HYDROXYPROGESTERONE; KETOCONAZOLE; LETROZOLE; LUTEINIZING HORMONE; PHENYTOIN; PLACEBO; PRASTERONE SULFATE; RIFAMPICIN; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTHRALGIA; BONE DENSITY; BONE METABOLISM; BREAST CANCER; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE MARKER; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVITY; ENZYME BINDING; FATIGUE; FOLLOW UP; FRACTURE; GYNECOLOGIC DISEASE; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INSOMNIA; KIDNEY DISEASE; LIPID METABOLISM; LIVER DISEASE; LYMPH NODE METASTASIS; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SWEATING; THROMBOEMBOLISM; TISSUE DISTRIBUTION; TREATMENT DURATION; VAGINA BLEEDING; VAGINA DISCHARGE; VISUAL DISORDER;

EID: 33846922067     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200605040-00005     Document Type: Review

References (56)

1. Crucitta E, Fornier MN, Locopo N, et al. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (review). Int J Oncol 2002 Jun; 20 (6): 1283-8
2. Clemett D, Lamb HM. Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 2000 Jun; 59 (6): 1279-96
3. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005 Jan 20; 23 (3): 619-29
4. Berry J. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clin Ther 2005 Nov; 27 (11): 1671-84
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998 May 16; 351 (9114): 1451-67
6. Nordenskjöld B, Rosell J, Rutqvist L-E, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005 Nov 2; 97 (21): 1609-10
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 May 14; 365 (9472): 1687-717
8. Boccardo F. Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. Clin Breast Cancer 2004 Sep; 5 Suppl. 1: S13-7
9. Buzdar AU, Robertson JFR, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002 Nov 1; 95 (9): 2006-16
10. Pfizer. Aromasin (exemestane tablets): prescribing information (US) [online]. Available from URL: http://www.pfizer.com [Accessed 2006 Jan 23]
11. AstraZeneca Pharmaceuticals. Arimidex (anastrozole tablets): prescribing information (US) [online]. Available from URL: http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/ [Accessed 2006 Mar 3]
12. Novartis Pharmaceuticals Corporation. Femara (letrozole tablets): prescribing information (US) [online]. Available from URL: http://www. accessdata.fda.gov/scripts/cder/drugsatfda/ [Accessed 2006 Mar 3]
13. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. Intergroup Exemestane Study. N Engl J Med 2004 Mar 11; 350 (11): 1081-92
14. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005 Jan; 365 (9453): 60-2
15. Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1-98 Collaborative Group. N Engl J Med 2005 Dec 29; 353 (26): 2747-57
16. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov 6; 349 (19): 1793-802
17. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005 Sep 7; 97 (17): 1262-71
18. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. The Austrian Breast and Colorectal Cancer Study Group and the German Adjuvant Breast Cancer Group. Lancet 2005 Aug 6; 366 (9484): 455-62
19. Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005 Aug 1; 23 (22): 5126-37
20. Love RR, Hutson PR, Havighurst TC, et al. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Clin Cancer Res 2005 Feb 15; 11 (4): 1500-3
21. Markopoulos C, Chrissochou M, Michailidou A, et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 2005 Sep; 16 (8): 879-83
22. Markopoulos C, Polychronis A, Zobolas V, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005 Sep; 93(1): 61-6
23. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998 Sep; 4 (9): 2089-93
24. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997 Jul; 3 (7): 1101-8
25. Anker GB, Refsum H, Ueland PM, et al. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clin Chem 1999 Feb; 45 (2): 252-6
26. Evans TR, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992 Nov 1; 52 (21): 5933-9
27. Lønning PE, Geisler J, Krag L, et al. Lipid profile and homocysteine levels in postmenopausal women with early breast cancer at low risk treated for two years with exemestane: follow-up results of a randomized, placebo-controlled study [abstract no. 4108 plus poster]. 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio (TX)
28. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA 2002 Oct; 288 (16): 2015-22
29. Jannuzzo MG, Poggesi I, Spinelli R, et al. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 2004 Jun; 53 (6): 475-81
30. Spinelli R, Jannuzzo MG, Poggesi I, et al. Pharmacokinetics (PK) of Aromasin® (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV) [abstract no. 1185]. Eur J Cancer 1999 Sep; 35 Suppl. 4: 295
31. Jannuzzo MG, Spinelli R, Poggesi I, et al. Inhibition of CYP3A4 does not influence Aromasin® (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV) [abstract no. 1184]. Eur J Cancer 1999 Sep; 35 Suppl. 4: 294
32. Poggesi I, Jannuzzo MG, Di Salle E, et al. Effect of food and formulation on the pharmacokinetics (PK) and pharmacodynamics (PD) or a single oral dose of exemestane (Aromasin®, EXE) [abstract no. 741]. Proc Am Soc Clin Oncol 1999; 18: 193a
33. Persiani S, Poggesi I, Cicioni P, et al. Pharmacokinetics of repeated low-doses of exemestane (1, 2.5, 5, and 10mg) in postmenopausal healthy volunteers [abstract no. 952]. Eur J Cancer 1995 Nov; 31 Suppl. 5: S198
34. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006 Feb 20; 24 (6): 910-7
35. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone biomarker data [abstract no. 5076 plus poster]. 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio (TX)
36. Bertelli G, Hall E, Bliss JM, et al. Intergroup Exemestane Study: results of the endometrial sub-protocol [abstract no. 402]. Breast Cancer Res Treat 2004; 88 Suppl. 1: 35. Plus poster presented at the 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8-11; San Antonio (TX)
37. Coombes RC, Hall E, Snowdon CF, et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen - updated survival analysis [abstract no. 3]. Breast Cancer Res Treat 2004; 88 Suppl. 1: 7. Plus oral presentation at the 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8-11; San Antonio (TX)
38. Coombes RC, Paridaens R, Jassem J, et al. First mature analysis of the Intergroup Exemestane Study [abstract no. LBA527]. J Clin Oncol 2006 Jun 20; 24 (18): 933s. Plus oral presentation at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)
39. Lønning PE, Geisler J, Krag LE, et al. Changes in bone metabolism after 2 years' treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: follow-up (FU) results of a randomized placebo-controlled study [abstract no. 531]. J Clin Oncol 2005 Jun 1; 23 (16 Suppl.): 11. Plus poster presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL)
40. Dowsett M. Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Semin Oncol 2003 Aug; 30 (4 Suppl. 14): 58-69
41. Howell A. New developments in the treatment of postmenopausal breast cancer. Trends Endocrinol Metab 2005 Nov; 16 (9): 420-8
42. Ingle JN. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin Cancer Res 2005 Jan 15; 11 (2 Pt 2): 900-5s
43. Baum M. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control 2004 Jul-Aug; 11 (4): 217-21
44. Mouridsen HT, Robert NJ. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. MedGenMed 2005; 7 (3): 20
45. Mouridsen HT, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 2005 Aug; 41 (12): 1678-89
46. Kudchadkar R, O'Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005; 55 (3): 145-63
47. Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 2005 Aug; 93 Suppl. 1: S23-7
48. Gradishar WJ. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005; 69 (1): 1-9
49. Lønning PE. Exemestane for breast cancer prevention: a feasible strategy? Clin Cancer Res 2005 Jan 15; 11 (2 Pt 2): 918-24s
50. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006 Mar; 42 (8): 1044-51
51. Thompson D, Taylor DCA, Montoya EL, et al. Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer [abstract no. 5037]. Breast Cancer Res Treat 2005; 94 Suppl. 1: 218. Plus poster presented at the 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio (TX)
52. Younis T, Rayson D, Dewar R, et al. Modeling for cost-effective strategies in adjuvant hormonal therapy for postmenopausal women with breast cancer: upfront aromatase inhibitors vs sequential tamoxifen-aromatase inhibitors [abstract no. 5089]. Breast Cancer Res Treat 2005; 94 Suppl. 1: 237-8. Plus poster presented at the 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio (TX)
53. Risebrough NA, Verma S, Trudeau M, et al. Economic evaluation of switching to exemestane at 2.5 years versus continuing tamoxifen as adjuvant therapy in early breast cancer: a Canadian perspective [abstract no. 2050]. Breast Cancer Res Treat 2005; 94 Suppl. 1: 101. Plus poster presented at the 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio (TX)
54. Skedgel C, Rayson D, Dewar R, et al. Cost-utility evaluation of adjuvant hormonal options in postmenopausal women with breast cancer: tamoxifen vs. anastrazole vs. tamoxifen then exemestane [abstract no. 5036]. Breast Cancer Res Treat 2005; 94 Suppl. 1: 217-8. Plus poster presented at the 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio (TX)
55. Gil JM, Lluch A, González P, et al. Pharmacoeconomic analysis of exemestane versus tamoxifen as adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer [abstract no. PCN15]. Value Health 2005 Nov-Dec; 8 (6): 37-8. Plus poster presented at the 8th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2005 Nov 6-8; Florence
56. Lønning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006 Feb; 17 (2): 217-25